Deborah Layton

1.8k total citations
64 papers, 1.1k citations indexed

About

Deborah Layton is a scholar working on Pharmacology, Cardiology and Cardiovascular Medicine and Toxicology. According to data from OpenAlex, Deborah Layton has authored 64 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pharmacology, 15 papers in Cardiology and Cardiovascular Medicine and 13 papers in Toxicology. Recurrent topics in Deborah Layton's work include Inflammatory mediators and NSAID effects (15 papers), Pharmacovigilance and Adverse Drug Reactions (13 papers) and Pharmaceutical studies and practices (8 papers). Deborah Layton is often cited by papers focused on Inflammatory mediators and NSAID effects (15 papers), Pharmacovigilance and Adverse Drug Reactions (13 papers) and Pharmaceutical studies and practices (8 papers). Deborah Layton collaborates with scholars based in United Kingdom, Netherlands and United States. Deborah Layton's co-authors include Saad Shakir, Lynda V. Wilton, Gillian Pearce, Emma Heeley, David W. J. Clark, Scott Harris, Lynda Wilton, Vicki Osborne, David W. Clark and A. Boshier and has published in prestigious journals such as The Lancet, Epilepsia and Osteoporosis International.

In The Last Decade

Deborah Layton

61 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Deborah Layton United Kingdom 24 342 220 203 155 132 64 1.1k
Liberata Sportiello Italy 24 254 0.7× 241 1.1× 149 0.7× 110 0.7× 78 0.6× 76 1.6k
Concetta Rafaniello Italy 28 286 0.8× 252 1.1× 265 1.3× 193 1.2× 101 0.8× 98 2.2k
Luisa Ibáñez Spain 21 248 0.7× 122 0.6× 171 0.8× 189 1.2× 60 0.5× 52 1.4k
Cristina Scavone Italy 26 190 0.6× 199 0.9× 308 1.5× 148 1.0× 94 0.7× 107 1.9k
Maurizio Sessa Denmark 21 144 0.4× 240 1.1× 232 1.1× 145 0.9× 66 0.5× 96 1.3k
Bengt‐Erik Wiholm Sweden 14 309 0.9× 163 0.7× 101 0.5× 166 1.1× 63 0.5× 27 986
B.‐E. Wiholm Sweden 23 217 0.6× 195 0.9× 104 0.5× 233 1.5× 80 0.6× 35 1.7k
L. V. Wilton United Kingdom 15 161 0.5× 129 0.6× 119 0.6× 226 1.5× 54 0.4× 22 816
Hitomi Teramachi Japan 16 161 0.5× 294 1.3× 63 0.3× 119 0.8× 109 0.8× 174 1.2k
Victoria Rollason Switzerland 18 176 0.5× 61 0.3× 149 0.7× 205 1.3× 126 1.0× 50 1.3k

Countries citing papers authored by Deborah Layton

Since Specialization
Citations

This map shows the geographic impact of Deborah Layton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Layton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Layton more than expected).

Fields of papers citing papers by Deborah Layton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Layton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Layton. The network helps show where Deborah Layton may publish in the future.

Co-authorship network of co-authors of Deborah Layton

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Layton. A scholar is included among the top collaborators of Deborah Layton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Layton. Deborah Layton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Fitzpatrick, R, et al.. (2025). Cancer Therapy-Induced Cardiotoxicity: Results of the Analysis of the UK DEFINE Database. Cancers. 17(2). 311–311. 1 indexed citations
3.
4.
Gray, Christen M., Matthew P. Fox, Timothy L. Lash, et al.. (2024). Use of quantitative bias analysis to evaluate single‐arm trials with real‐world data external controls. Pharmacoepidemiology and Drug Safety. 33(5). e5796–e5796. 5 indexed citations
5.
Osborne, Vicki, Amie Goodin, Joshua D. Brown, et al.. (2024). Updated core competencies in pharmacoepidemiology to inform contemporary curricula and training for academia, government, and industry. Pharmacoepidemiology and Drug Safety. 33(4). e5789–e5789.
6.
Lysen, Thom S., Hanne van Ballegooijen, Peter Rijnbeek, et al.. (2023). Impact of European Union Label Changes for Fluoroquinolone-Containing Medicinal Products for Systemic and Inhalation Use: Post-Referral Prescribing Trends. Drug Safety. 46(4). 405–416. 14 indexed citations
7.
Khatib, Yasmin, et al.. (2023). Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review. Frontiers in Pharmacology. 14. 1137983–1137983. 7 indexed citations
8.
9.
Behr, Elijah R., et al.. (2017). Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort. BMJ Open. 7(10). e016627–e016627. 23 indexed citations
10.
Mantel‐Teeuwisse, Aukje K., Y. Buggy, Deborah Layton, et al.. (2012). Reasons for and Time to Discontinuation of Rimonabant Therapy. Drug Safety. 35(12). 1147–1158. 4 indexed citations
11.
Layton, Deborah, Moira Dryburgh, Thomas M. MacDonald, Saad Shakir, & Isla S. Mackenzie. (2011). Pilot Swine Flu Vaccination Active Surveillance Study: Final Results. Drug Safety. 34(10). 889–890.
12.
Mackenzie, Isla S., Thomas M. MacDonald, Saad Shakir, et al.. (2011). Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self‐reporting of serious adverse events and pregnancy outcomes. British Journal of Clinical Pharmacology. 73(5). 801–811. 37 indexed citations
13.
Layton, Deborah, et al.. (2010). New Postgraduate Qualifications in Pharmacovigilance from the Drug Safety Research Unit in the UK. Drug Safety. 34(1). 89–91. 2 indexed citations
14.
Mackenzie, Isla S., Moira Dryburgh, Derek Rutherford, et al.. (2010). Participation of General Practices in a Swine Flu Vaccination Study. Drug Safety. 33(10). 911–911. 1 indexed citations
15.
Osborne, Vicki, Lorna Hazell, Deborah Layton, & Saad Shakir. (2010). Drug Utilization of Intrinsa® (Testosterone Patch) in England. Drug Safety. 33(3). 213–221. 4 indexed citations
16.
Layton, Deborah, Vanessa Marshall, A. Boshier, Peter S. Friedmann, & Saad Shakir. (2006). Serious Skin Reactions and Selective COX-2 Inhibitors. Drug Safety. 29(8). 687–696. 32 indexed citations
17.
Layton, Deborah, Emma Heeley, & Saad Shakir. (2004). Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data. Journal of Clinical Pharmacy and Therapeutics. 29(2). 171–181. 5 indexed citations
18.
19.
20.
Heeley, Emma, et al.. (2001). Prescription-event monitoring and reporting of adverse drug reactions. The Lancet. 358(9296). 1872–1873. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liberata Sportiello Breakdown of academic impact, for papers by Concetta Rafaniello Breakdown of academic impact, for papers by Luisa Ibáñez Breakdown of academic impact, for papers by Cristina Scavone Breakdown of academic impact, for papers by Maurizio Sessa Breakdown of academic impact, for papers by Bengt‐Erik Wiholm Breakdown of academic impact, for papers by B.‐E. Wiholm Breakdown of academic impact, for papers by L. V. Wilton Breakdown of academic impact, for papers by Hitomi Teramachi Breakdown of academic impact, for papers by Victoria Rollason
Rankless by CCL
2026